Novartis Gender Discrimination Trial Begins; Company Consultant Found Problems in 2003
This article was originally published in The Pink Sheet Daily
Executive Summary
Women sales reps claim Novartis discriminates in pay and promotion; Novartis attorney says company implemented consultant's recommendations and has made progress in promoting women.
You may also be interested in...
Successful Novartis Sales Reps' Performance Scores Could Be Downgraded To Satisfy Budget Goals, Gender Discrimination Trial Reveals
Former head of human resources testifies at gender discrimination trial that 12 percent of a given employee population had to receive low performance ratings.
Successful Novartis Sales Reps' Performance Scores Could Be Downgraded To Satisfy Budget Goals, Gender Discrimination Trial Reveals
Former head of human resources testifies at gender discrimination trial that 12 percent of a given employee population had to receive low performance ratings.
Legal Briefs: AstraZeneca Wins Seroquel Suit, King Settles With DoJ, Sanofi Resolves Gender Discrimination Suit
AstraZeneca wins first Seroquel product liability trial: A New Jersey state court jury reached a verdict in favor of AstraZeneca, rejecting a plaintiff's claims that the antipsychotic caused his diabetes. The case, Baker v. AstraZeneca, is the first to go to trial. AstraZeneca is facing more than 14,000 Seroquel (quetiapine) lawsuits involving more than 22,000 plaintiffs alleging the company failed to adequately warn of the risk of diabetes. Nine previous cases set for trial were dismissed. The company said that in these cases and in the Baker suit, the facts showed that the plaintiffs either already had diabetes or had so many pre-existing risk factors that they had a significantly increased risk of diabetes before taking Seroquel